PA8584501A1 - Nuevos derivados de oxazol - Google Patents

Nuevos derivados de oxazol

Info

Publication number
PA8584501A1
PA8584501A1 PA20038584501A PA8584501A PA8584501A1 PA 8584501 A1 PA8584501 A1 PA 8584501A1 PA 20038584501 A PA20038584501 A PA 20038584501A PA 8584501 A PA8584501 A PA 8584501A PA 8584501 A1 PA8584501 A1 PA 8584501A1
Authority
PA
Panama
Prior art keywords
oxazol
new derivatives
compounds
ppara
diabetes
Prior art date
Application number
PA20038584501A
Other languages
English (en)
Inventor
Alfred Binggeli
Markus Boehringer
Uwe Grether
Hans Hilpert
Georges Hirth
Hans-Peter Maerki
Markus Meyer
Peter Mohr
Fabienne Ricklin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8584501A1 publication Critical patent/PA8584501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I) EN DONDE R1 A R6 Y N SON TAL COMO SE DEFINE EN LA DESCRIPCION Y REIVINDICACIONES, Y SALES Y ESTERES ACEPTABLES FARMACEUTICAMENTE DE LOS MISMOS. LOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO Y/O PREVENCION DE ENFERMEDADES, QUE ESTAN MODULADAS POR AGONISTAS PPARA Y/O PPARY COMO POR EJEMPLO DIABETES TIPO II.
PA20038584501A 2002-10-07 2003-10-06 Nuevos derivados de oxazol PA8584501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02022286 2002-10-07

Publications (1)

Publication Number Publication Date
PA8584501A1 true PA8584501A1 (es) 2004-05-21

Family

ID=32049977

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038584501A PA8584501A1 (es) 2002-10-07 2003-10-06 Nuevos derivados de oxazol

Country Status (32)

Country Link
US (2) US6969725B2 (es)
EP (1) EP1551814B1 (es)
JP (1) JP4414886B2 (es)
KR (1) KR100623819B1 (es)
CN (1) CN100415727C (es)
AR (1) AR041481A1 (es)
AT (1) ATE402153T1 (es)
AU (1) AU2003273949B2 (es)
BR (1) BR0315114A (es)
CA (1) CA2499721C (es)
CO (1) CO5540385A2 (es)
DE (1) DE60322408D1 (es)
DK (1) DK1551814T3 (es)
ES (1) ES2311110T3 (es)
GT (1) GT200300218A (es)
HK (1) HK1083339A1 (es)
HR (1) HRP20050308A2 (es)
IL (1) IL167250A (es)
MX (1) MXPA05003392A (es)
MY (1) MY143576A (es)
NO (1) NO330171B1 (es)
NZ (1) NZ538465A (es)
PA (1) PA8584501A1 (es)
PE (1) PE20040591A1 (es)
PL (1) PL208743B1 (es)
PT (1) PT1551814E (es)
RU (1) RU2303593C2 (es)
SI (1) SI1551814T1 (es)
TW (1) TWI343915B (es)
UY (1) UY28006A1 (es)
WO (1) WO2004031162A1 (es)
ZA (1) ZA200502664B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
TWI343915B (en) * 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
OA12960A (en) * 2002-11-15 2006-10-13 Cadila Healthcare Ltd Substituted aralkyl derivatives.
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
GB2460784A (en) * 2007-03-07 2009-12-16 Dong A Pharmtech Co Ltd Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition
RU2361581C2 (ru) 2007-09-14 2009-07-20 Закрытое Акционерное Общество "Мастерклон" Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний
KR20110082145A (ko) * 2008-10-21 2011-07-18 메타볼렉스, 인코포레이티드 아릴 ｇｐｒ１２０ 수용체 작동약 및 이의 용도
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
US8637096B2 (en) 2009-12-04 2014-01-28 Curtis C. Stojan Compositions and method for enhancing insulin activity
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CN102285933B (zh) 2010-06-18 2016-03-09 浙江海正药业股份有限公司 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用
EP2758041B1 (de) 2011-09-20 2021-01-13 Basf Se Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
EP0992503B1 (en) * 1998-03-30 2004-02-04 Japan Tobacco Inc. Process for producing isooxazolidinedione compound
KR100388120B1 (ko) * 1998-05-11 2003-06-18 다케다 야쿠힌 고교 가부시키가이샤 저혈당 및 저지질혈 활성을 갖는 옥시이미노알칸산 유도체
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
IL145732A0 (en) * 1999-04-06 2002-07-25 Sankyo Co α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
DE10031657A1 (de) 2000-06-29 2002-01-24 Siemens Ag Hochfrequenz-Bauelement
MXPA03001558A (es) * 2000-08-23 2003-06-06 Lilly Co Eli Agonistas del receptor activado del proliferador de peroxisoma.
AU2002342244B2 (en) 2001-05-15 2005-06-16 F. Hoffmann-La Roche Ag Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes
TWI343915B (en) * 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists

Also Published As

Publication number Publication date
JP4414886B2 (ja) 2010-02-10
WO2004031162A1 (en) 2004-04-15
BR0315114A (pt) 2005-08-16
NO20051011L (no) 2005-05-02
CA2499721C (en) 2011-03-15
AU2003273949A1 (en) 2004-04-23
SI1551814T1 (sl) 2008-10-31
DE60322408D1 (de) 2008-09-04
GT200300218A (es) 2004-05-24
TW200409761A (en) 2004-06-16
NO330171B1 (no) 2011-02-28
AU2003273949B2 (en) 2007-04-05
RU2005114373A (ru) 2006-05-10
MY143576A (en) 2011-05-31
DK1551814T3 (da) 2008-10-27
KR100623819B1 (ko) 2006-09-13
CN100415727C (zh) 2008-09-03
MXPA05003392A (es) 2005-06-22
PL208743B1 (pl) 2011-06-30
RU2303593C2 (ru) 2007-07-27
CA2499721A1 (en) 2004-04-15
NZ538465A (en) 2007-08-31
PT1551814E (pt) 2008-09-22
AR041481A1 (es) 2005-05-18
CN1703406A (zh) 2005-11-30
EP1551814A1 (en) 2005-07-13
PL376363A1 (en) 2005-12-27
ZA200502664B (en) 2006-02-22
PE20040591A1 (es) 2004-08-30
TWI343915B (en) 2011-06-21
ATE402153T1 (de) 2008-08-15
HRP20050308A2 (en) 2006-07-31
EP1551814B1 (en) 2008-07-23
ES2311110T3 (es) 2009-02-01
IL167250A (en) 2010-12-30
CO5540385A2 (es) 2005-07-29
KR20050055750A (ko) 2005-06-13
US7348349B2 (en) 2008-03-25
US6969725B2 (en) 2005-11-29
US20050267180A1 (en) 2005-12-01
JP2006504709A (ja) 2006-02-09
US20040116487A1 (en) 2004-06-17
HK1083339A1 (en) 2006-06-30
UY28006A1 (es) 2004-04-30

Similar Documents

Publication Publication Date Title
PA8566101A1 (es) Nuevos derivados de piridina y pirimidina
PA8566201A1 (es) Nuevos derivados de piridina y quinolina
PA8557001A1 (es) Nuevos derivados de pirrolidina
PA8544901A1 (es) Derivados de oxazol
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
PA8562801A1 (es) Nuevos derivados de pirido (2,1-a) isoquinolina
CR8147A (es) Derivados de pirido 2, 1a-isoquinolina, como inhibidores de dpp-iv
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
GT200600206A (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilizacion
CR9980A (es) Imidazolinas 4,4,5,5 tetrasustituidas
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
CR11620A (es) Derivados de Imadazo-[1,2,b]-Piridazina para el Tratamiento de Enfermedad Mediada por Cinosa de Tirosina C-Met
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
PA8584501A1 (es) Nuevos derivados de oxazol
EA201000098A1 (ru) Производные хиназолинамида
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
HN2003000063A (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades.
PA8589801A1 (es) Aminoalcoxiindoles
PA8581201A1 (es) Nuevos derivados de tiazol
GT200100145A (es) Derivados de pirrolidina.
UY29308A1 (es) Derivado de quinolina, su uso, preparación y medicamento que lo contiene